医学
结合
荟萃分析
内科学
肿瘤科
抗体-药物偶联物
药品
抗体
实体瘤
药理学
免疫学
单克隆抗体
数学
癌症
数学分析
作者
Leyin Zhang,Deyi Shen,Lulin Yu,Yici Yan,Harpreet Wasan,Jinping Yu,Shuo Zhang,Leitao Sun
标识
DOI:10.1016/j.critrevonc.2022.103758
摘要
Antibody-drug conjugates (ADCs) show significant advantages in cancer treatment due to their high selectivity and anti-tumor activity, but the efficacy and safety of the treatment of solid tumors are unknown. We searched research databases, major conference proceedings and trial registries for randomized controlled trials (RCTs). Then, we selected qualified studies and extracted dates. Studies were assessed for quality, and a meta-analysis was conducted to quantify effects of ADCs on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and adverse events (AEs). The within-study heterogeneity was evaluated by subgroup and sensitivity analysis. Eleven RCTs with 4353 participants were included. ADCs had better PFS (HR: 0.69, 95 % CI: 0.56–0.82) and OS (HR: 0.76, 95 % CI: 0.61–0.92). ADCs resulted in lower risk of febrile neutropenia in blood system. Conversely, ADC therapy had not a prepotent on ORR (RR: 1.36, 95 % CI: 0.71–2.60).
科研通智能强力驱动
Strongly Powered by AbleSci AI